Amgen sues Novartis in US court to block generic osteoporosis, bone cancer drugs


Share post:

Amgen Inc sued Novartis AG’s Sandoz in a federal court in the United States on Monday (May 1), accusing Sandoz’s proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.

Amgen asked the New Jersey court to block Sandoz’s biosimilars of the drugs until its patents expire. One of the patents named in the complaint does not expire until 2037.

Sandoz declined to comment on the lawsuit on Tuesday. Novartis, which is also named in the complaint, is preparing to spin Sandoz off into a standalone company later this year.

Amgen’s Prolia is used to treat osteoporosis. Xgeva, with the same active ingredient denosumab, treats bone cancer and prevents fractures in bone-cancer patients.

Amgen said the proposed biosimilars infringe 21 patents covering Prolia and Xgeva.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

Shadow Health Minister Preet Kaur Gill visits pharmacy in Staffordshire

Preet Kaur Gill, Shadow Minister for Primary Care and Public Health, has paid a recent visit to a...

Superdrug to halt single-use vape sales in UK, Ireland due to environmental concerns

British pharmacy chain Superdrug has announced plans to cease the sale of disposable vapes in all its UK...

Closure of temporary registers by 31 March 2024: GPhC

Pharmacists on the temporary register will be automatically removed on April 1, unless they have applied to rejoin the...

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...